Morgan Stanley
LRMR icon

Morgan Stanley’s Larimar Therapeutics LRMR Stock Holding History

Morgan Stanley’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.89M Buy
420,813
+284,830
+209% +$1.14M ﹤0.01% 4807
2025
Q4 		$518K Buy
135,983
+42,980
+46% +$167K ﹤0.01% 5496
2025
Q3 		$300K Sell
93,003
-76,035
-45% -$285K ﹤0.01% 5724
2025
Q2 		$489K Sell
169,038
-242,342
-59% -$561K ﹤0.01% 5467
2025
Q1 		$884K Buy
411,380
+241,201
+142% +$762K ﹤0.01% 5059
2024
Q4 		$659K Buy
170,179
+20,951
+14% +$138K ﹤0.01% 5304
2024
Q3 		$977K Buy
149,228
+95,615
+178% +$768K ﹤0.01% 5051
2024
Q2 		$389K Buy
53,613
+6,324
+13% +$48.4K ﹤0.01% 5403
2024
Q1 		$359K Sell
47,289
-65,139
-58% -$508K ﹤0.01% 5465
2023
Q4 		$512K Buy
112,428
+88,094
+362% +$297K ﹤0.01% 5605
2023
Q3 		$96.1K Sell
24,334
-8,052
-25% -$30.4K ﹤0.01% 5911
2023
Q2 		$101K Sell
32,386
-32,002
-50% -$131K ﹤0.01% 5947
2023
Q1 		$292K Sell
64,388
-476,449
-88% -$2.49M ﹤0.01% 5526
2022
Q4 		$2.23M Buy
540,837
+10,544
+2% +$36K ﹤0.01% 4382
2022
Q3 		$1.7M Buy
530,293
+485
+0.1% +$1.22K ﹤0.01% 4544
2022
Q2 		$1.04M Sell
529,808
-176
-0% -$520 ﹤0.01% 4997
2022
Q1 		$2.15M Buy
529,984
+518,189
+4,393% +$3.39M ﹤0.01% 4471
2021
Q4 		$127K Sell
11,795
-23,265
-66% -$259K ﹤0.01% 6298
2021
Q3 		$404K Buy
35,060
+472
+1% +$5.66K ﹤0.01% 5626
2021
Q2 		$339K Buy
34,588
+8,471
+32% +$95.7K ﹤0.01% 5742
2021
Q1 		$382K Sell
26,117
-6,938
-21% -$126K ﹤0.01% 5307
2020
Q4 		$708K Sell
33,055
-20,745
-39% -$416K ﹤0.01% 4859
2020
Q3 		$816K Buy
53,800
+18,112
+51% +$229K ﹤0.01% 4354
2020
Q2 		$459K Sell
35,688
-105,579
-75% -$1.23M ﹤0.01% 4644
2020
Q1 		$1.3M Sell
141,267
-446
-0.3% -$5.86K ﹤0.01% 3736
2019
Q4 		$1.89M Sell
141,713
-1,966
-1% -$18.8K ﹤0.01% 4087
2019
Q3 		$1.27M Buy
143,679
+128,295
+834% +$1.41M ﹤0.01% 4139
2019
Q2 		$220K Buy
15,384
+9,249
+151% +$246K ﹤0.01% 4983
2019
Q1 		$202K Sell
6,135
-14,250
-70% -$730K ﹤0.01% 5055
2018
Q4 		$1.21M Buy
20,385
+16,192
+386% +$1.6M ﹤0.01% 4137
2018
Q3 		$589K Buy
4,193
+55
+1% +$6.68K ﹤0.01% 4903
2018
Q2 		$508K Buy
4,138
+1,465
+55% +$124K ﹤0.01% 5090
2018
Q1 		$238K Buy
2,673
+2,343
+710% +$199K ﹤0.01% 5398
2017
Q4 		$18K Buy
330
+223
+208% +$10K ﹤0.01% 6103
2017
Q3 		$5K Sell
107
-3,188
-97% -$133K ﹤0.01% 6292
2017
Q2 		$139K Buy
3,295
+40
+1% +$2.05K ﹤0.01% 5499
2017
Q1 		$182K Sell
3,255
-5,309
-62% -$264K ﹤0.01% 5364
2016
Q4 		$327K Buy
8,564
+5,858
+216% +$238K ﹤0.01% 5148
2016
Q3 		$107K Sell
2,706
-6,604
-71% -$300K ﹤0.01% 5277
2016
Q2 		$670K Buy
9,310
+2,981
+47% +$236K ﹤0.01% 4262
2016
Q1 		$507K Sell
6,329
-3,856
-38% -$304K ﹤0.01% 4435
2015
Q4 		$768K Buy
10,185
+6,360
+166% +$1.02M ﹤0.01% 4240
2015
Q3 		$1.47M Buy
3,825
+2,361
+161% +$1.06M ﹤0.01% 3786
2015
Q2 		$608K Buy
1,464
+858
+142% +$359K ﹤0.01% 4574
2015
Q1 		$288K Buy
606
+507
+512% +$241K ﹤0.01% 5002
2014
Q4 		$37K Sell
99
-5,123
-98% -$1.32M ﹤0.01% 5894
2014
Q3 		$1.23M Buy
+5,222
New +$1.18M ﹤0.01% 3865

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Morgan Stanley's LRMR Position: Q1 2026 in Review

Morgan Stanley increased its Larimar Therapeutics (LRMR) stake by 209% in Q1 2026, buying an estimated $1.14M and bringing the position to 420,813 shares worth $1.89M. The position accounts for ﹤0.01% of the portfolio, ranked #4807.

Morgan Stanley first reported a position in LRMR in Q3 2014 and has held it in 47 quarters since. The position peaked at $2.23M in Q4 2022. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Morgan Stanley held 420,813 shares of Larimar Therapeutics worth $1.89M as of Q1 2026.
  • Morgan Stanley bought 284,830 Larimar Therapeutics shares in Q1 2026, an estimated $1.14M.
  • Larimar Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4807 holding.
  • Morgan Stanley first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 47 quarters since.
  • Morgan Stanley's Larimar Therapeutics position peaked at $2.23M in Q4 2022.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.